Form 4: 4D Molecular Therapeutics Chief Legal Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• On August 19, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options to acquire 500 shares of common stock at a price of $6.49 per share.
• Simultaneously, Bizily sold 500 shares of common stock at $15 per share.
• These transactions were executed under a pre-existing 10b5-1 trading plan adopted on October 10, 2023.
• Following these transactions, Bizily directly owns 6,781 shares of 4D Molecular Therapeutics common stock and 10,879 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions by an officer under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to monitor potential alignment between management's actions and company performance.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider trading activity.
• The sale of shares could have a minor impact on the stock price, but is unlikely to be significant given the relatively small volume.

Key Dates